AI Summary

The investigational inhaled drug mosliciguat, a soluble guanylate cyclase activator, is moving into a new phase of clinical development. In a randomized phase‑2 trial, mosliciguat produced marked and consistent effects in patients with pulmonary hypertension associated with interstitial lung disease (PH‑ILD), a particularly challenging form of pulmonary vascular disease. The study’s results highlight the drug’s potential to address this rare lung disease combination, supporting further development of the therapy.

AI summaries can be wrong sometimes—always verify important details using the source article.